Showing 2411-2420 of 3039 results for "".
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- Grants Available for Students, Residents to Attend Neuro-Optometric Rehabilitation Association 2023 Conferencehttps://modernod.com/news/grants-available-for-students-residents-to-attend-neuro-optometric-rehabilitation-association-2023-conference-2023-conferenc/2481463/The Neuro-Optometric Rehabilitation Association International (NORA) is offering up to 10 students and residents with an interest in neuro-rehabilitation an opportunity to apply for a student grant (
- Harrow Announces Appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilancehttps://modernod.com/news/harrow-announces-appointment-of-mark-mannebach-phd-rph-as-head-of-regulatory-affairs-and-pharmacovigilance/2481449/Harrow announced the appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the company’s portfolio of new and existing products. Dr. Mannebach
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Harrow Launches Next-Generation Compounded Atropine Formulationshttps://modernod.com/news/harrow-launches-next-generation-compounded-atropine-formulations/2481410/Harrow announced the launch of its patent-pending, next-generation compounded atropine formulations. The formulations are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. According to Harrow, the ImprimisRx
- Visionix Launches Optovue Solix FullRange OCThttps://modernod.com/news/visionix-launches-optovue-solix-fullrange-oct/2481409/Visionix USA has introduced the Optovue Solix FullRange OCT in North America. Featuring 120kHz ultra-high-speed scanning, Optovue Solix FullRange OCT features anterior 18 x 6.25 scans, new posterior high-density scan patterns for more detail and better precision, int
- Researchers Identify Potential Cause of Keratoconushttps://modernod.com/news/researchers-identify-potential-cause-of-keratoconus/2481402/Researchers at the University of North Texas Health Science Center are the first to characterize extracellular vesicles (EVs) in the tears of patients with keratoconus, according to an National Eye Institute news release. Dimitrios Karamichos, PhD, executive director of the North